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Chronic disease usually spans years of a person’s lifetime and includes a disease free period, a preclinical, or 
latent period, where there are few overt signs of disease, a clinical period where the disease manifests and is 
eventually diagnosed, and a follow-up period where the disease might progress steadily or remain stable. It is 
often of interest to investigate the relationship between risk factors measured at a point in time (usually during the 
disease free or preclinical period), and the development of disease at some future point (e.g., 10 years later). We 
outline some popular designs for the identification of subjects and discuss issues in measurement of risk factors 
for analysis of chronic disease. We discuss some of the complexities in these analyses, including the time 
dependent nature of the risk factors and missing data issues. We then describe some popular statistical modeling 
techniques and outline the situations in which each is appropriate. We conclude with some speculation toward 
future development in the area of chronic disease data and analysis. 
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A chronic disease is a disease first characterized 
by  a   development   period  or  latent period  in 
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which the disease progresses subclinically. The 
latent period can be extensive in time. For 
example, in cardiovascular disease, build up of 
plaque in the arteries can begin in childhood. 
During this latent period the person often 
displays no overt effects or problems. Then the 
disease manifests itself in a clinical phase.  
 With cardiovascular disease, this may 
begin with a myocardial infarction (heart attack) 
where the heart suffers permanent injury due to 
the blockage caused by the plaque. After the 
appearance of the clinical phase, the affected 
person (or host) may follow a course that leads 
to little or substantial deterioration and possibly 
death.  
 In this example of cardiovascular 
disease, the clinical phase is initiated by a 
clinical  event,  a heart attack, and then followed 
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by a post event phase where there may be a 
general weakening of the body which increases 
the risk of subsequent cardiovascular events 
such as a second heart attack or a stroke 
resulting in death. 
 Lung cancer is an example of another 
chronic disease. Here the subclinical, latent 
period can consist of lung tumors developing 
over a period of more than 10 years before 
clinical manifestation and diagnosis.  After 
diagnosis, there can be periods of stabilization, 
remission and progression.  AIDS is still 
another example, where the subclinical stage 
can be characterized by a positive HIV 
infection. The clincal manifestation of AIDS 
may then appear followed by a series of 
infections, increased deterioration and 
ultimately death.  Alzheimer’s disease provides 
an example where the distinction between the 
preclinical stage and clinical stage is blurred.  In 
the preclinical phase, there is a progressive 
decline in cognitive function, especially noted in 
short term memory, and often personality 
changes.  These ultimately lead to a stage where 
the person is unable to care for him or herself.  
The diagnosis of Alzheimer’s disease often 
results when the person is debilitated and other 
forms of dementia (e.g., caused by a series of 
strokes) are ruled out. 
 
 
A simple model for chronic disease is as follows:                   (1) 
 
 





Interest focuses on all four components.  Each 
presents detailed and sophisticated modeling, 
data collection and analytic issues.  Consider, 
for example, the ‘Disease Free  -> Preclinical 
(Latent Period) -> Clinical Manifestation’ 
component.  This can be further refined to three 
submodels (shown below) where DF represents 
a completely disease-free state, PC represents 
preclinical signs and symptoms and C 
represents disease manifestation (clincal): 
 
  DF      PC  C    (2.1) 
 
    PC1  
  DF      
    PC2  C    (2.2) 
 
  DF      PC  C    (2.3) 
 
 
In (2.1), the disease free (DF) stage leads to the 
preclinical (PC) stage which in turn leads 
directly to the clinical stage (C).  In such a 
situation knowledge of the preclinical stage 
could be useful in delaying or averting the 
clincal stage (C).  Simple models of breast and 
colon cancer fit this situation.  In (2.2), the 
disease free (DF) stage can lead to preclinical 
stages 1 or 2 (PC1 and PC2, respectively).  PC1 
does not progress to the clinical stage (C) while 
PC2 does.  In this situation, identification of the 
preclinical stage (PC) does not imply that the 
clincal stage (C) follows.  Cervical cancer is an 
example of this situation.  Lastly, (2.3) displays 
a situation where the preclinical stage (PC) may 
actually revert to the completely disease free 
(DF) stage or may lead to the clinical (C) stage. 
 We could extend and elaborate the 
second component of model (1) ‘Clinical 
Manifestation -> Follow-Up’ in a similar 
fashion incorporating the complexities that are 
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involved in diagnosing the presence of the 
disease and the follow-up after that.   
 Chronic disease data and analysis 
questions relate to all aspects of the above 
(disease free, preclinical, clinical manifestation 
and follow-up). Good statistical approaches 
involve hypothesizing models for these aspects, 
collecting appropriate data, and then fitting and 
testing the appropriate models.  Before fitting 
statistical models, biological models need to be 
formulated.  Both (1) and (2) above represent 
simple models.   
 One important set of models relate risk 
factors (RF) of a disease free individual to the 
probability of manifestation of the clinical stage 
of the disease.  For example, the relationship 
between age, gender, smoking status, blood 
pressure and cholesterol to the development of a 
myocardial infarction could be modelled as: 
 
 
 Risk Factors    Clinical Manifestation 
 Age 
 Gender 
 Smoking Status                 Myocardial Infarction   (3) 
 Systolic Blood Pressure 




 To turn this into a statistical model one 
needs to decide how to identify appropriate 
(disease free) subjects, how many subjects to 
sample, when to measure the risk factors and 
how long to follow them. The latter item of 
follow-up is to ensure that a sufficient number 
develop a myocardial infarction so the 
components (or parameters) of the mathematical 
model can be estimated with good precision.  
 In a later part of this article we discuss 
in more detail the methods of statistical 
modeling for chronic disease. We discuss some 
popular designs for studies of chronic disease 
and we use cardiovascular disease as an 
example throughout the discussion. We review 
some of the methodologic issues that arise in 
studies of chronic disease and outline some 
popular statistical modeling and analysis 
techniques. We conclude with some speculation 
towards future developments. In the next section 
we present an example to motivate the 
discussion that follows. 
 
2. Motivation: Cardiovascular Disease Example 
 Consider a study of cardiovascular 
disease, in particular a study of the risk factors 
associated with the development of 
cardiovascular disease. A first challenge is to 
understand the outcome, and in particular the 
conditions that should be considered part of the 
outcome and how they should be measured. A 
second challenge is to determine which risk 
factors should be measured and how frequently 
they should be measured in the study subjects. 
A related challenge is the specification of the 
appropriate statistical model to relate candidate 
risk factors to the outcome. In the following we 
illustrate the complexities of each step using 
cardiovascular disease as an example. 
 Defining the Outcome. Cardiovascular 
disease includes a number of conditions and is a 
major cause of morbidity and mortality 
worldwide. The most common serious 
cardiovascular disease is coronary heart disease 
(also called cardiac ischemia, defined as 
insufficient blood supply due to atherosclerosis 
of the coronary arteries). It consists of 
myocardial infarction (heart attack), which is 
direct damage to the heart, coronary deaths, and 
angina (persistent chest pain due to cardiac 
ischemia). Cardiovascular disease also includes 
other conditions such as stroke (or brain attack), 
and peripheral artery disease (circulation 
problems often in the calves). Cardiovascular 
disease is believed to have a long preclinical or 
latent stage.  
 For example, patients with coronary 
heart disease (CHD) are diagnosed (and enter 
the clinical stage) in a variety of ways. One 
patient may present with angina at an early 
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stage while another may suffer a heart attack 
after an otherwise asymptomatic history. 
Accurate determination of a cardiovascular 
event is critical, and the technologies to 
determine specific events are evolving over 
time. At one time an MI was mainly diagnosed 
by electocardiogram. Now it is standard to use 
enzyme tests (e.g., SGOT and CPK) Often 
chronic disease outcomes include condition-
specific mortality (e.g., death due to 
cardiovascular disease). In such cases, elaborate 
protocols are required to ascertain outcome 
status. These include, in some cases, reviewing 
death certificates and/or hospital records. 
Determining cause of death can be further 
complicated by incomplete or ambiguous 
specification of the cause of death by the 
medical personnel evaluating the death. 
 Specifying the Risk Factors and the 
Data Collection Schedule. Determining the risk 
factors associated with the development of 
chronic disease (e.g., cardiovascular disease) 
requires an understanding of the biological 
complexity of the disease, some of which might 
change over time. Generally, studies of 
cardiovascular disease consider the following 
risk factors: gender, age, blood pressure, 
cholesterol, smoking status, and history of 
diabetes. Cardiovascular diseases span decades 
of individuals lives (from the preclinical to the 
clinical and follow-up stages).  
 Studies of cardiovascular disease often 
take years to complete, with the duration of the 
study influenced by the time it takes to observe 
a sufficient number of outcome events. The 
importance and influence of risk factors may 
vary over time (e.g., obesity at an early age and 
maintained over time may be important in 
leading to cardiovascular disease while the most 
recent blood pressure may be more important 
than blood pressure measured decades earlier). 
So, often risk factors are measured at the outset, 
and then repeated over the follow-up period. 
Investigators must decide what intervals are 
most appropriate to obtain repeat measurements. 
The interval is influenced by the stability (or 
lack of) of the risk factors over time.  
 For example, total cholesterol level is a 
relatively stable risk factor whereas smoking 
status is not. The latter would need to be 
measured on a more frequent basis. In recent 
studies of cardiovascular disease, investigators 
consider genetic and environmental factors, 
along with a broader array of clinical risk 
factors. In some cases, investigators have the 
flexibility to add new risk factors to a data 
collection protocol during an ongoing study. 
This introduces an analytic issue in that these 
new risk factors will not be measured on the 
same schedule as the core set (i.e. those 
measured since the outset). In cardiovascular 
disease, surgical procedures have also advanced 
rapidly in the last two decades and include 
introduction of artificial aortic valves, open 
heart surgery, angioplasty (opening blocked 
arteries using balloon catheters) and regulation 
of heart rythms by implanted pacemakers. 
 In parallel, pharmacologic treatments 
have become increasingly effective in treating 
known risk factors of cardiovascular disease 
(e.g., hypertension, hyperlipidemia) thereby 
slowing the manifestation and progression of 
disease. It is important to measure these 
interventions, which generally modify the 
effects of the risk factors on the development of 
disease, along with the risk factors themselves. 
Designs for studies of chronic disease and 
methologic issues that arise in studies of chronic 
disease are discussed in detail in Section 3. 
 Choosing the Correct Model. The 
choice of the appropriate statistical model 
should be based primarily on a biological 
model. It should also be influenced by specific 
aspects of the design such as whether subjects 
are followed for a fixed period of time and then 
determined to have or not have the disease at the 
end of the observation period or whether 
subjects are followed for different amounts of 
time and have disease status ascertained at the 
end of the observation period. In a study of 
cardiovascular disease, a subject might die 
during the observation period due to cancer (or 
some disease other than cardiovascular disease) 
and at the time of death be free of 
cardiovascular disease. The most appropriate 
statistical model is one that utilizes all of the 
information that was measured on this person 
rather than exclude him or her because of the 
complexity of the data. Popular statistical 
models for studies of chronic disease are 
discussed in detail in Section 4. 
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3. Designs, Subject Selection and Data for 
Studies of Chronic Disease 
 The data for studies of the relationship 
between risk factors and development and 
progression of chronic disease can be 
prospective, retrospective or cross-sectional. 
Prospective study designs involve identifying 
individuals who are free of the disease of 
interest and following them over time. These 
studies can include repeated measurements of 
risk factors over time and monitoring for the 
development and progression of disease. The 
schedule for following individuals and repeating 
measurements depends on a number of factors 
including the stability of the risk factors over 
time and the nature of the relationship between 
the risk factors and disease status over time. 
Retrospective studies (also called case control 
studies) usually involve identifying two groups 
of individuals; those with the disease of interest 
(often called cases) and matches who are free of 
the disease of interest (often called controls). 
 Data are collected retrospectively usually 
by way of individual’s recollection of prior 
health and risk behaviors or through medical 
record review. These studies are not optimal. It 
is usually difficult to assemble representative 
groups of cases and controls. Often the cases 
represent either the sickest (e.g., subjects 
enrolled through an Alzheimer’s clinic) or the 
healthiest (e.g., those who have not died) of 
those affected with the disease. Further, the 
controls often differ in many ways from the 
cases, confounding the comparison of cases and 
controls. In addition, these studies can be 
subject to a number of biases (for example, 
recall bias or inaccurate recollection of specific 
behaviors or measurment based on incomplete 
medical records). 
 Cross-sectional studies are conducted at a 
point in time and represent concurrent risk 
factor and disease status. In some cross-
sectional studies, individuals provide historical 
data on risk behaviors on the basis of 
recollection, thereby also subjecting these 
studies to recall bias.  
 Longitudinal cohort studies are most well 
suited for the analysis of chronic disease. We 
now describe in detail the specifics of 
longitudinal cohort studies and outline a well 
known study of cardiovascular disease, the 
Framingham Heart Study. 
 
3.1. Longitudinal Cohort Studies: The 
Framingham Heart Study 
 In longitudinal cohort studies, a group or 
cohort of individuals is assembled at the outset. 
The inclusion criteria often require a set of 
individuals to be free of the disease of interest. 
This is not always the case and those with 
prevalent disease may be enrolled at the outset. 
Individuals are followed prospectively in time. 
Serial measurements can be taken on a 
predetermined schedule, often at fixed time 
intervals (e.g., measurements every 2 years or 
every 5 years). Outcome or disease status is 
measured over time. For those individuals who 
develop disease, measures of the progression or 
severity of disease are also taken. There are 
several, large longitudinal cohort studies of 
cardiovascular disease, probably the best known 
study is the Framingham Heart Study, described 
below. 
 The Framingham Heart Study began in 
1948 and is one of the most ambitious and 
daring longitudinal medical studies ever 
initiated. A cohort of 5,209 individuals, 2336 
males and 2873 females, was enrolled from 
Framingham, MA. These represented a 60% 
sample of the town with ages from 28 to 62 
years. Multiple risk factors were measured 
biennially, and the study continues today with 
surviving participants involved for over 50 
years. Major cardiovascular risk factors have 
been measured since the outset (e.g., blood 
pressure, total cholesterol and smoking status) 
while others have been introduced as they were 
hypothesized to have an impact on the 
develoment of cardiovascular disease (e.g., 
HDL cholesterol, LDL cholesterol, 
homocystene and fibrinogen). Development of 
cardiovascular events is recorded over time 
including coronary heart disease (and its 
components; myocardial infarction, coronary 
death and angina), stroke, intermittent 
claudication (a peripheral arterial disease), 
congestive heart failure and cardiovascular 
disease death. Intense efforts continue to be 
utilized to gather complete information on every 
subject. There are some missing data due to 
subjects moving from the area or discontinuing 
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participation (which is minimal). The total loss 
to follow-up is less than 3 percent. The 
Framingham Heart Study was expanded in 1971 
to include a cohort of the offspring of the 
original participants and their spouses. These 
data allow for an investigation of the evolution 
of new detection technologies such as 
echocardiogram and carotid ultrasound and the 
study of the effects of genetics on development 
of cardiovascular and other chronic diseases 
such as dementia. 
 
3.2. Methodological Issues in Chronic Disease 
Studies 
 There are a number of major methodologic 
issues that arise in longitudinal studies, two are 
discussed here. The first issue is based on 
changing definitions of risk factors and 
outcomes over time. For example, technological 
advances have resulted in better diagnostic tests 
for determining the presence or absence of 
chronic disease. Studies utilizing better 
diagnostic tests might observe more outcome 
events and possible different relationships 
between risk factors and disease. In some 
chronic diseases (e.g., diabetes) medical 
specialists have revised the clinical criteria for 
diagnosing an individual (e.g., different 
threshold criteria on laboratory tests).  
 Even the definition of myocardial infarction 
has chenged over time. In the late 1940s, its 
determination was based mainly on 
electrocardiogram. Later, enzyme tests, SGOT 
and CPK, became standard components of the 
definition of myocardial infarction starting in 
the mid 1950s and proceeding during the 1960s. 
In other areas, more sensitive assays have been 
developed over time for measuring risk factors 
(e.g., HDL and LDL cholesterol). As 
modifications occur during a study, analysts 
must take steps to make the data as comparable 
over time as possible. The same applies when 
making comparisons to external studies, these 
may have employed different definitions and 
assays. 
 A second methodological issue in 
longitudinal studies concerns missing data. 
Even when intensive surveillance programs are 
in place, such as those used in the Framingham 
Heart Study, there are often situations where 
complete data is not gathered on every subject. 
In longitudinal studies of chronic disease, there 
are instances where data are missing because 
subjects fail to show up at scheduled 
examinations, fail to complete certain 
assessments even when attending the 
examination, or drop out during the course of 
the study. These circumstances produce unequal 
numbers of repeated measurements on different 
individuals. There are several approaches for 
performing analysis in the presence of missing 
data. 
 First, analysis can be restricted to only those 
individuals with complete data. This approach is 
not optimal in terms of efficiency and is biased 
in some situations. A second approach involves 
imputing or ascribing values for the missing 
values and then analyzing the revised dataset. 
There are sophisticated procedures and software 
packages available for this imputation and 
subsequent analysis. This analysis can be biased 
and can artifically improve precision. A third 
approach involves analyzing the incomplete 
dataset (i.e., without attempting to impute 
values for the missing data). 
 Statistical techniques and associated 
computer software (e.g., mixed models) exist 
that take advantage of all available data and 
minimize bias that are associated with analysis 
restricted to only individuals with complete data 
or analysis of imputed data. These techniques, 
however, require assumptions about the non-
response or the missing data mechanisms. If 
these assumptions are incorrect, these models 
can also produce biased results.  
 The most appropriate analytic techniques in 
the presence of missing data are those closely 
tied to the underlying missing data mechanism. 
When the missingness does not depend on the 
value of the complete or missing outcome, the 
data are said to be missing completely at 
random. Data are missing completely at random 
if the probability of observing a missing value 
does not depend on current or future data. For 
example, if a data monitor forgets to ask a 
patient if he or she has persistent chest pains 
(angina) the missingness has nothing to do with 
this subject’s cardiovascular health. A less strict 
assumption about the missing data mechanism 
is one in which the missingness is related only 
to the data observed (and not related to 
unmeasured or missing data). 
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 This missing data mechanism is called 
missing at random and the probability of 
observing a missing value depends on past data 
but does not depend on current or future data. 
For example, missing at random results when 
missingness is related to past cardiovascular 
health but is independent of unavailable current 
or future cardiovascular health. Data that are 
missing completely at random or missing at 
random are said to be ignorable and to produce 
a valid analysis it is not necessary to model the 
missing data mechanism explicitly. Appropriate 
analysis that include variables related to the 
mechanism for missingness produce unbiased 
results. 
 The final classification of missing data 
mechanisms is called nonignorable missingness. 
If the probability of observing a missing value 
depends on unmeasured current and future data, 
the missingness is nonignorable. An example 
would be a subject who fails to show up for an 
evaluation because his/her health has started to 
deteriorate. The deterioration continues, and if 
outcomes were measured, they would reflect the 
decline. When missing data are nonignorable, it 
is critical to model the missing data mechansim 
explicitly in statistical models otherwise results 
will be biased. 
 Even with these classifications for missing 
data and the available statistical techniques and 
software, there is no formal means to test which 
mechanism is operating in a given situation. The 
validity of the analysis often depends heavily 
upon the assumptions of the technique. 
Therefore, analysis and interpretation of results 
in the presence of missing data are often open to 
criticism. The best recommedation for handling 
missing data is to avoid it wherever possible.  
 
4. Analytic Techniques for Chronic Disease 
Modeling 
 After the sample is selected and the risk 
factors, the outcomes and the sampling 
schedule determined, mathematical/statistical 
modeling is needed to tie these together. 
Several analytic techniques can be applied to 
investigate this relation of the risk factors to 
the development and progression of chronic 
disease. Some of these are designed 
specifically to relate baseline risk factors to 
disease development. Some are able to exploit 
the time dependent nature of the risk factors 
and the outcome events. We now describe 
some popular techniques. 
 
4.1 Logistic Regression Analysis: 
Dichotomous Outcome 
 Logistic regression analysis can examine 
and quantify the effects of risk factors on the 
development of disease. The outcome of 
interest is dichotomous (e.g., development or 
non-development of chronic disease over a 
time period), and the independent variables or 
risk factors can include continuous or discrete 
characteristics. The logistic regression model 










where Y is a dichotomous outcome variable 
(e.g., 0=no chronic disease, 1=chronic disease) 
and p=P(Y=1) is the probability of a subject 
with the disease, x1, x2, …, xp are the risk 
factors, and β1, β2,…βp are the regression 
parameters reflecting how the risk factors 
affect the log of the odds of developing 
disease.  Logistic regression analysis is a very 
useful technique for analyzing dichotomous 
outcomes and the individual is considered the 
unit of analysis. 
 Logistic regression analysis is appropriate 
in studies of chronic disease where originally 
disease free subjects are followed for a pre-
specified observation period and at the end of 
the observation period, each subject can  be 
classified as having developed the disease or 
not.  In many studies of chronic disease, there 
are often have a number of individuals for 
whom we do not have data at the end of the 
observation period and the last time they were 
observed they had not yet developed disease.  
Logistic regression can not deal directly with 
these subjects.  The analysts must arbitrarily 
drop them from analyses or assume a disease 
status at the end of the observation period.  
The techniques described in the next section 
can handle this and other issues that arise in 
longitudinal studies of chronic disease. 
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4.2 Survival Analysis: Time to Event Data 
 Survival analysis includes a set of 
techniques that deal with time until the event 
of interest occurs (e.g., onset of disease).  It is 
often the case in studies of chronic disease that 
there are many patients who do not develop 
the disease or for whom we do not know if 
they ever develop the disease.  This happens 
when the disease is rare, when patients are lost 
to follow-up (e.g., move away but do not 
develop the disease), when patients die during 
the observation period but are free of the 
disease of interest at the time of death, or 
when they drop out of the study (e.g., due to 
lack of interest). 
 In all of these situations, we do not have 
the time to the development of disease.  
However, these individuals can contribute a 
substantial amount of information (up to the 
end of the observed time period when we 
know they are disease free) – information 
which can be utilized through survival analytic 
techniques.  It is this aspect of the data that 
distinguish survival analysis techniques from 
other statistical techniques. 
 These observations in which we know the 
individual is disease free for some period of 
time, but do not know if they developed the 
disease in other time periods are called 
censored observations.  There are several 
different types of censoring, the most common 
in studies of chronic disease is right censoring.  
Right censored obervations are observations in 
which we do not observe the time to event 
because if it occurs it occurs after the last 
observation point. 
 Some survival models are based on 
parametric assumptions about the distribution 
of the survival function, while others are not 
(parametric and nonparameteric models, 
respectively).  A useful method to characterize 
survival is by the hazard function (the 
instantaneous rate of developing disease).  
There are a number of popular parametric 
survival models.  The exponential model is 
perhaps the simplest, but assumes constant 
hazard over time and is therefore not generally 
applied to chronic disease data.  The Weibull 
distribution model is a generalization of the 
exponential model and is popular for 
analyzing chronic disease risk (e.g., cancer 
risk) and the hazard function is given by the 
following: 
 
1γλγth(t) −=  
 
where λ=-ln(p)/t and p=P(disease free at time 
t).  The hazard at time t, h(t), increases as t 
increases for γ>1 and decreases as t increases 
if 0<γ<1.  The exponential model is a special 
case of the Weibull model with γ=1 (constant 
risk with time). 
 Survival analysis methods can be used to 
assess the effects of risk factors on the 
development of chronic disease.  There are 
several models that are appropriate for this 
purpose.  A popular parametric model for 
analysis of chronic disease is the accelerated 





where t reflects the time until disease onset, 
h0(t) is the baseline hazard at time t (i.e., the 
hazard if all of the risk factors were set to 
zero), β'x=β1x1 +  β2x2 + . . . + βpxp, x1, x2, 
…, xp are the risk factors, and β1, β2,…βp 
are the regression parameters. 
 A popular “nonparametric” survival 
analysis model is the proportional hazards 
model (also called the Cox regression model), 
and it is commonly used to assess the relative 
impact of a set of risk factors measured at a 
point in time (baseline) on survival and 
assumes that additive differences in risk 
factors are related to multiplicative changes in 
the hazard function. 
 The proportional hazards model can also 
be used to assess the impact of time-dependent 
covariates (i.e., risk factors that change over 
time) on the hazard function and on survival.  
This is a particularly useful feature of the 
model in studies of chronic disease as 
individuals may undergo procedures during 
the observation period which alter their 
prognosis.  For example, an individual’s risk 
of cardiovascular disease may change after 
undergoing coronary artery bypass surgery.  
The form of the Cox model is: 
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)xβ...xβx(t)exp(βhh(t) pp22110 +++=  
 
where h(t) is the hazard at time t, h0(t) is the 
baseline hazard at time t (i.e., the hazard if all 
of the risk factors were set to zero), and as 
above x1, x2, …, xp are the risk factors, β1, 
β2,…βp are the regression parameters 
reflecting how the risk factors affect the 
hazard. The risk factors, xi above, can be 
variables measured at some baseline period or 
variables that vary over time (called time 
dependent variables).The proportional hazards 
model is actually a semi-parametric model 
because the distribution of the underlying 
hazard is not specified.  
 Estimating the risk of developing chronic 
disease per se or assessing the effects of a set 
of risk factors on the development of chronic 
disease may be complicated by a common 
situation in studies of chronic disease, namely, 
the competing risk of other diseases or death. 
For example, in studying the relation of risk 
factors to the development of coronary heart 
disease the competing risk of someone 
developing stroke needs to be considered. 
Similarly, in examining the relation of 
cigarette smoking to lung cancer the 
competing risk of developing a heart attack 
before the lung cancer is a real possibility. 
 Recently, there have been major efforts 
to estimate the lifetime risk of developing 
chronic diseases such as breast cancer, 
coronary heart disease and Alzheimer’s 
disease. A major methodological issue 
involves the handling of death which can 
occur before the chronic disease, such as 
Alzheimer’s disease, develops. 
 
4.3 Longitudinal Data Analysis: Mixed 
Models, Generalized Linear Models and 
Generalized Estimating Estimating Equations 
 A key feature of chronic disease data is 
the repeated aspect of the measurements. In 
longitudinal studies with multiple 
measurements taken on a set of individuals 
over time, analytic techniques must take into 
account the correlation between measurements 
taken on the same individual. An added 
complexity is the unbalanced nature of the 
data due to different numbers of 
measurements taken on different subjects. We 
now describe some popular methods for 
analyzing incomplete longitudinal data; mixed 
models and generalized estimating equations. 
 Mixed models procedures assume that 
measurements taken over time are correlated 
and that regression coefficients vary randomly 
across subjects according to a specified 
distribution. In these applications, some of the 
effects are modeled as fixed (e.g., the effects 
of risk factors on outcome, called within 
subjects effects) and some as random 
(between subject effects). These mixed effects 
models are also referred to as random 
coefficients models, growth curve models or 
hierarchical models. They can also be 
extended to incorporate time-dependent 
covariates. 
 In these mixed effects models a parametric 
structure is assumed also for the covariances 
of the repeated measurements. There are many 
distinct structures that can be assumed, 
including the independence structure (all 
observations are independent), compound 
symmetry (the correlation between any two 
observations is equal to some common value), 
autoregressive, and unstructured (no 
specification of the structure of the 
correlations). 
 Currently available statistical computing 
packages offer many of these structures as 
options in their mixed models applications. 
Estimates of the fixed effects and the 
covariances of the random effects can be 
estimated using maximum likelihood using 
Newton-Raphson techniques or the 
Expectation Maximization (EM) algorithm. 
The estimates of the covariances are biased 
because they do not take into account the 
estimation of the fixed effects and therefore it 
is recommended that these be estimated using 
restricted maximum likelihood which 
produces unbiased estimates. Estimates of the 
standard errors of effects are robust for large 
samples. 
 Mixed models are appealing models for 
longitudinal data as they are flexible and 
handle unbalanced data in a highly efficient 
manner. It is important to note that these 
models produce consistent estimates (unbiased 
for large samples) only when data are missing 
D’AGOSTINO, SR. & SULLIVAN 
 
237 
at random or missing completely at random. 
These models require careful specification of 
the fixed and random effects and a covariance 
structure. When appropriate specifications are 
made, the final estimates of the fixed and 
random effects, as well as the magnitude of 
the variance components are statistically 
correct and highly informative. 
 A generalized linear model is a model in 
which a specific link function (e.g., binomial, 
Poisson, Gamma) is specified to relate the 
mean (or expected) value of the outcome to a 
linear function of the risk factors. This has the 
effect of transforming the data to a linear 
model, but involves correct specification of 
the link or distribution of the outcome 
variable. Parameters of the model are 
estimated through maximum likelihood. The 
appropriateness of the estimates in a 
generalized linear model are highly dependent 
on the distributional assumptions.  
 Generalized estimating equations (GEE) 
are used to analyze correlated data (e.g., data 
measured on the same subject over time) that 
could otherwise be analyzed using a 
generalized linear model but require fewer 
distributional assumptions than generalized 
linear models, making them more appealing. 
The method of estimation is an extension of 
least squares. 
 Generalized estimating equations produce 
consistent estimates (unbiased for large 
samples) and robust standard errors for large 
samples. Generalized estimating equations are 
appropriate when interest lies in “marginal” 
effects (i.e., effects averaged over all 
individuals) rather than subject-specific 
effects. The approach is now available in 
many statistical computing packages and again 
requires specification of a covariance 
structure. It is appropriate under the 
asusmption of data missing completely at 
random. 
 
4.4 Tree-Based Classification Methods 
 Still another set of techniques for relating 
risk factors to development of chronic disease 
are tree-based classification methods. These 
include a number of applications which are 
intuitively appealing, many of which are based 
on a technique called binary recursive 
partitioning. 
 In binary recursive partitioning, a dataset 
is partitioned first into two distinct groups on 
the basis of the risk factor that best 
discriminates the groups in terms of disease 
status (present or absent). The process is 
recursive in that this partitioning continues 
until pre-specified stopping criteria are met 
(e.g., the final groups represent the last 
statistically significant splits). The outcome of 
these analyses is in the form of a clinical 
prediction rule or algorithm that resembles a 
tree where the branches represent splits on a 
risk factor. 
 Figure 1 illustrates a simple tree where 
there are two splits. The first split is on the 
basis of age (over 65 years versus 65 years and 
younger). A second split is made among those 
65 years of age and younger on the basis of 
systolic blood pressure (less than 130 mm Hg 
versus 130 or more mm Hg). Persons over 65 
years of age have a 25% probability of 
developing coronary heart disease. Persons 65 
years of age and younger with systolic blood 
pressure less than 130 have a 1% probability 
of developing CHD, while persons 65 years of 
age and younger with systolic blood pressure 
of 130 or more have a 20% probability of 
developing CHD. 
 When the outcome is dichotomous 
(presence or absence of chronic disease) the 
rule can be used to classify patients, on the 
basis of specific criteria, as likely or unlikely 
to develop the disease. The criteria are based 
on specific values of risk factors. These 
models are particularly appealing to clinicians 
as they mirror common practice. For example, 
a physician might gather information from a 
patient on his/her risk factors (e.g., systolic 
blood pressure, smoking status, alcohol 
consumption), and may conduct a series of 
laboratory tests (e.g., total Cholesterol level, 
HDL cholesterol, triglycerides). Based on this 
information, the clinician can appeal to the 
empirical tree-based prediction rule to classify 
the subject as likely or not likely to develop 
the disease. These methods can also be used to 
estimate the probability that this patient will 
develop chronic disease.  
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Figure 1.   Tree-Based Classification Methods: Example of A Simple  
   Classification Tree for Coronary Heart Disease (CHD) 
 
 
        10% with CHD  
 
   Age > 65     Age < 65 
 
       25% with CHD        9% with CHD 
 
   Classify as High Risk 
      SBP < 130    SBP > 130 
 
           1% with CHD      20% with CHD 
 




4.5 Neural Networks 
 Neural network models are a large class of 
elaborate mathematical techniques used for 
developing prediction rules. They are now 
becoming popular methods for predicting 
chronic disease. They are very flexible 
prediction models that can accommodate large 
datasets (i.e., many risk factors and large 
sample sizes) and more complex relationships 
among the variables. 
 
4.6 Model Building 
 All of the above methods often involve a 
development phase and a validation phase. 
Investigators split a dataset into two distinct 
parts, one part is used for developing the 
model and the other part is used to evaluate 
how the model performs (the validation 
phase). 
 
5. Future Directions 
 The collection and analyses of chronic 
disease data have evolved over time to a new 
level of sophistication. The development of 
new statistical methodologies for longitudinal 
data analysis and analysis of complex systems, 
coupled with advances in statistical 
computing, have greatly influenced the 
statistical analysis of chronic disease data. As 
health care delivery systems continue to strive 
for quality, more data will be collected and 
available for analysis of chronic disease (and 
also for acute and epidemic disease). 
Longitudinal data will be available on many 
subjects thereby allowing for more complete 
investigations of risk factors and interactions 
between risk factors. 
 Advances in statistical computing 
software will also allow for the estimation of 
more complex statistical models, not restricted 
to those which assume linear associations 
between risk factors and chronic disease. 
Finally, as more data become available on 
families, analysis of chronic disease will include 
exploration of genetic factors on the 
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